Settling on an Increased NCI Budget

Publication
Article
OncologyONCOLOGY Vol 14 No 10
Volume 14
Issue 10

The final numbers are not in yet, but there is no doubt that Congress will fund the National Cancer Institute (NCI) at a considerably higher level than the $3.505 billion the Clinton administration asked for. That fiscal 2001 request was already nearly 6% above the actual 2000 budget.

The final numbers are not in yet, but there is no doubt that Congress will fund the National Cancer Institute (NCI) at a considerably higher level than the $3.505 billion the Clinton administration asked for. That fiscal 2001 request was already nearly 6% above the actual 2000 budget. The House approved $3.793 billion and the Senate went one better—to $3.804 billion. At the end of July, a House and Senate conference committee agreed to a compromise budget number for all the NIH institutes. Those numbers were not available at press time but were planned for release by October. It is safe to assume that the NCI budget will be somewhere between the House and Senate number. The size of the increase, of course, is good news. But the House and Senate enumerated a number of specific cancer research areas they expected to get more attention.Those “earmarks” can sometimes cause problems between cancer advocacy groups. The House, for example, lists 18 separate areas it expects the NCI to get a move on, including esophageal and stomach cancers, endometrial and cervical cancers, lung cancer screening, and urologic cancers.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content
OSZAR »